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Summary The respective roles of Epstein-Barr virus (EBV) and c-myc in the pathogenesis of endemic
Burkitt's lymphoma (BL) are unclear. In order to help resolve the question whether constitutive expression of
the c-myc gene in an EBV-immortalised B cell is sufficient to induce a tumorigenic phenotype, B cells from a
common marmoset (Callithrixjacchus) were immortalised with EBV, transfected with a constitutively activated
c-myc gene and inoculated into the host animals. Despite the cell line transfected with c-myc displaying
enhanced growth characteristics, in vitro and in vivo experiments demonstrated that this was not sufficient to
induce a tumorigenic phenotype. This supports our previous findings with EBV-immortalised human B cells
transfected with an activated c-myc gene (Hotchin et al., 1990).
Endemic BL is a monoclonal B cell tumour characterised by
the presence of a human herpesvirus, Epstein-Barr virus
(EBV) and a chromosome translocation involving the c-myc
proto-oncogene on chromosome 8 and the IgH locus on
chromosome 14, or, more rarely the Ig ic or k loci on
chromosome 2 or 22 (Lenoir, 1986). The result of such a
translocation is constitutive activation ofthe c-myc gene. It is
widely accepted that other co-factors must be involved in the
aetiology of endemic BL, a prime candidate being malaria
which is holoendemic in regions where the endemic form of
BL is found (Kafuko & Burkitt, 1970).
C-Myc is a nuclear protein with homology to a number of
sequence-specific DNA-binding proteins (Cole, 1990). Recent
data has indicated that c-Myc forms a heterodimeric complex
with a protein called Max, and that this complex acts a
sequence-specific transcriptional activating factor (Blackwood
& Eisenman, 1991; Amati et al., 1992; Kretzner et al., 1992).
Until recently the role of c-myc in both normal and malig-
nant cells was unclear. Myc is clearly important in cellular
proliferation, being expressed at low or undetectable levels in
resting or quiescent cells, but induced to high levels in
mitotically activated cells (Kelly et al., 1983). Furthermore
anti-sense transcripts have been used to demonstrate that
c-myc is required for cell proliferation (Prochownik et al.,
1988). More recently, it has been shown that, in the presence
of high levels of c-Myc, cells are unable to withdraw from
the cell cycle, and when deprived of nutrients undergo pro-
grammed cell death (apoptosis) (Evan et al., 1992). On the
basis of these data Evan et al. (1992) propose a model for
myc function whereby c-myc provides a fail-safe mechanism
to prevent uncontrolled proliferation and acts as a regulator
of cell fate.
Deregulated c-myc expression is found in a number of
mammalian tumours (Spencer & Groudine, 1991) indicating
the potential importance of this gene in tumorigenesis. Early
experiments, introducing exogenous activated c-myc genes
into fibroblasts, resulted in an immortalised, but not fully
transformed, phenotype (Land et al., 1983; Mougneau et al.,
1984; Land et al., 1986). In transgenic mice, linking c-myc to
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the Ig;t promoter resulted in the development of B cell
lymphomas (Adams et al., 1985). The monoclonality of these
tumours, however, suggested that other factors in addition to
activation of c-myc were necessary for development of these
tumours. This was supported by data from co-transfection
experiments demonstrating cooperation between myc and ras
resulting in a transformed phenotype (Land et al., 1986).
More recently it has been shown that c-Myc induced apop-
tosis can be overcome by constitutive expression of the bcl-2
proto-oncogene (Fandini et al., 1992; Bissonnette et al., 1992)
which is known to inhibit apoptosis in B-cells (Vaux et al.,
1988; Hockenbury et al., 1990). Interestingly, whilst expres-
sion of bcl-2 could rescue cells from apoptosis and allow
indefinite proliferation in the absence of mitogenic stimuli,
morphological transformation was not evident (Fandini et
al., 1992).
The majority of EBV infections are subclinical and occur
early in life, with over 90% of the adult population demon-
strating evidence of past infection (Henle & Henle, 1979). If
primary infection is delayed past the age of 12 years then a
common consequence of infection with EBV is infectious
mononucleosis (IM), a usually benign, self-limiting lympho-
proliferative disease. EBV is also associated with a number of
other pathological conditions, including nasopharyngeal
carcinoma (NPC), oral hairy leukoplakia and lymphopro-
liferative disease in patients with severe T-cell immunosup-
pression. In common with other herpesviruses, EBV persists
for life following primary infection, and is tightly controlled
by the cell mediated immune response (Rickinson, 1986).
The role of EBV in development of BL is unclear. EBV is
able to immortalise B cells in vitro to form lymphoblastoid
cell lines (LCL) which express a number of latency associated
proteins - EB nuclear antigens (EBNA-1-6), the latent mem-
brane protein (LMP) and two terminal proteins (TP1 and
TP2) (reviewed in Kieff & Liebowitz, 1990). However, the
two viral proteins implicated in this process, EBNA-2 (Ham-
merschmidt & Sugden, 1989) and LMP (Wang et al., 1985;
Baichwal & Sugden, 1985) are not expressed in BL (Rowe et
al., 1987a). LMP has also been shown to upregulate expres-
sion of bcl-2 and prevent apoptosis in BL cell lines (Hender-
son et al., 1991). However, Bcl-2 is unlikely to be involved in
development of BL as it is expressed only at low or undetec-
table levels in BL cells which most resemble the in vivo
phenotype (Henderson et al., 1991).
Lombardi et al. (1987) reported that transfection of an
activated c-myc gene into EBV immortalised B cell lines was
sufficient to induce a transformed phenotype. A subsequent
study transfecting the same plasmid constructs into a
different LCL found that, whilst the cells expressing a con-
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stitutively activated c-myc gene had altered surface phenotype
and a reduced serum dependency, they were not transformed
as determined by growth in semi-solid media and tumour
formation in nude mice (Hotchin et al., 1990).
In order to examine further the role of EBV and c-myc in
tumour development, common marmosets (Callithrix jac-
chus) were used as hosts for immortalised autologous B cells
containing a constitutively expressed c-myc gene. Inoculation
of the common marmoset with EBV results in apparently
asymptomatic infection as demonstrated by the presence of
IgG class antibodies to the viral capsid antigen (VCA) which
remain detectable for life (Wedderburn et al., 1984; N.W.
unpublished observations). In addition heterophile antibodies
and IgG antibodies against the viral early antigen (EA)
complex have also been detected in some common marmosets
infected with EBV (Wedderburn et al., 1984). Both of these
markers are typically found in IM in humans and, at least in
terms of the serological response to EBV, infection of com-
mon marmosets mimics the asymptomatic infection seen in
humans (Niederman et al., 1970; Henle & Henle, 1979).
Unlike cotton-top marmosets (Saguinus oedipus oedipus),
common marmosets do not develop lymphoproliferative or
malignant lesions in response to inoculation with EBV
(Miller, 1979; Wedderburn et al., 1984), thus the common
marmoset represents a better model than cotton-top mar-
mosets for studying, in vivo, the role of c-myc and EBV in
the pathogenesis of BL.
Materials and methods
Experimental animals
Triplet common marmosets, two females (244 and 245) and
one male (246), were used in these experiments. They were
born and raised in a colony to which there have been no
further additions since 1970.
removed from the plastic by incubation with 0.05°% trypsin,
0.02°% EDTA, washed and resuspended in 10 ml normal
culture medium. After 48 h hygromycin B was added to
100 tgml-'.
Serology
Serum samples were prepared from clotted peripheral blood
taken at regular intervals under anaesthesia from each
animal, and stored at - 20C until required. Antibody titres
against the EB viral capsid antigen (VCA) and early antigen
a
M 1 2
b
M 1 -2
Cell culture
M245 LCL is an EBV immortalised B cell line derived by
infecting cells from the peripheral blood ofmarmoset number
245 with the M81 strain of EBV (Desgranges et al., 1976)
which was isolated from a common marmoset LCL originally
transformed by a strain of EBV derived from a nasopharyn-
geal carcinoma (de The et al., 1970). Cells were cultured at
37°C in a 5% CO2 inctubator using RPMI 1640 containing
2mM L-glutamine, 100IU penicillin, 10lgmlm l strepto-
mycin and 10% foetal calf serum (FCS). For transfections
the amount of hygromycin B (Calbiochem) required to kill
non-transfected cells (100 gml-') was determined by titra-
tion.
PlasmidDNA constructions
pHEBoSVmycl,2,3 contains all three exons ofthe c-myc gene
under control of the SV40 early region promoter (Lombardi
et al., 1987) inserted into pHEBo, a plasmid which permits
episomal replication in EBV infected B cells and selection
with the antibiotic hygromycin B (Sugden et al., 1985).
pHEBoSVmycl,2,3 was a gift from Dr R. Dalla-Favera
(New York University School of Medicine).
Liposome mediated transfection
Liposome mediated transfection of M245 cells was carried
out using a commercially supplied reagent (Lipofectin, BRL).
Cells were adhered to 35 mm cell culture dishes coated with
4.51tl of a 10mgml-l solution of 'Cell-Tak' (BioPolymers
Inc.) by incubating 4 x 106cells in 2 ml 'Opti-MEM I'
medium (BRL) for 30 min at 37°C. After removing any
non-adherent cells 1 fg ofplasmid DNA was added to 0.5 ml
of OpiMEM I and which was mixed with 0.5 ml OpiMEM I
containing 10fg of 'Lipofectin' before adding to the ad-
herent cells. After a 5 h incubation at 37°C the cells were
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Figure 1 Detection of plasmid-derived c-myc transcripts in
M245-mycl23 using polymerase chain reaction (PCR). cDNAs
were generated from total cellular RNA isolated from M245 and
M245-mycl23 cell lines. Primers located in the SV40 early region
promoter and exon II of c-myc c, were annealed to the cDNAs
and sequences between the two primers amplified by PCR. The
PCR products were electrophoresed on an agarose gel, transfer-
red to a nylon membrane and probed with a 32P-labelled probe
for c-myc. a, ethidium bromide stained gel prior to transfer. b,
nylon membrane probed for c-myc sequences with 32P-labelled
probe. Track l, M245; track 2, M245-mycl23. Positions of
molecular weight markers are indicated (M). Sizes of markers, in
kb from the top of the gel are; 1.35, 1.08, 0.87, 0.60, 0.31,
0.28/0.27, 0.23, 0.19.928 N.A. HOTCHIN et al.
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Figure 2 Immunoblot analysis of c-Myc protein expression in
myc-transfected and untransfected common marmoset cells. Pro-
tein extracts were separated on an SDS-PAGE gel, transferred to
nitrocellulose and probed with an anti-c-Myc monoclonal anti-
body. Lane 1, M245 cells; lane 2, M245-mycl23 cells. Positions
of molecular weight standards (M) and c-Myc (+) are indicated.
(EA) were determined as described previously (Hotchin et al.,
1989). Heterophile antibody tests were performed using a
commercially available procedure (Monospot, Mercia diag-
nostics).
Immunocytochemistry
Detection of the Epstein-Barr virus nuclear antigen (EBNA)
complex was performed using anti-complement immuno-
fluorescence (ACIF) (Reedman & Klein, 1973) or anti-
complement immunoperoxidase staining (ACIPx) (Guohua et
al., 1981).
Haematology
Thin film blood smears were prepared from peripheral blood
and air dried. Following fixation in methanol the slides were
stained with May-Grunwald-Giemsa. The slides were coded
and differential counts performed on 200 cells per blood film
and expressed as a percentage by an independent observer.
Tumorigenicity assay
Growth of cells in semi-solid medium was determined as
previously described (Hotchin et al., 1990).
Detection ofplasmidderived c-myc transcripts
Total RNA was extracted from cells in log phase growth
using the guanidinium/caesium chloride method as described
by Maniatis et al. (1982). Plasmid-derived c-myc transcripts
were detected using the polymerase chain reaction as de-
scribed by Kawasaki et al. (1990). Briefly cDNA was
generated from 3lag total RNA using 10 units of reverse
transcriptase (Super RT, Anglian Biotechnology).
Oligonucleotide primers (20mers) corresponding to regions in
the SV40 early promoter/enhancer (GCTATTCCAGAAG-
TAGTGAG) and exon II of c-myc (CGAAGGTCATAGT-
TCCTGTTG) were synthesised on an ABI 380B DNA syn-
thesiser. PCR was carried out in the presence of 1 iLg of each
primer and 2.5 units ofTaq polymerase (Cetus Corporation).
Thirty cycles of 94°C (30 seconds), 60°C (30 seconds), 72°C
(2 min) were followed by a 5 min incubation at 72°C and
5 min at 25°C. Fifteen pl of each completed PCR reaction
was electrophoresed in a 1.8% agarose gel, transferred to
nylon membrane (Zeta-probe, Bio-Rad) by Southern blotting
(Maniatis et al., 1982) and hybridised to 32p labelled pHEBo-
SVmycl,2,3 as described (Westneat et al., 1988). 25 ng
pHEBo-SVmycl,2,3 was labelled with 50 LCi 32P dCTP using
a multiprime labelling system (Amersham).
Immunoblotting
Whole cell protein extracts were prepared, separated by SDS-
PAGE, transferred to nitrocellulose and immunoblotted as
described previously (Allday et al., 1988; Rowe et al., 1987b).
C-Myc was detected using a monoclonal antibody, Myc-9E10
(Evan et al., 1985). Mycl-9E10 was a gift from Dr G. Evan
(Imperial Cancer Research Fund, London).
Results
Establishment ofc-myc transfected marmoset LCL
M245 LCL was transfected with pHEBo- SVmycl23 using
Lipofectin and transfected cells selected with hygromycin B
(100 tgml-'). One drug resistant cell line was established
(M245-mycl23). Attempts to obtain a pHEBoSV transfected
control cell line proved unsuccessful and the parental M245
LCL was used as a control. To establish that the plasmid
derived c-myc gene was being expressed in M245-mycl23
cells, cDNAs were generated from total RNA using reverse
transcriptase. Plasmid derived transcripts were detected using
PCR to amplify sequences encompassed by primers in the
SV40 early region promoter/enhancer element and in the
second exon ofthe c-myc gene (Figure 1c). Results (Figure la
and b) clearly demonstrate the presence of plasmid derived
transcripts in M245-mycl23 but not in the control M245 cell
line. Use of primers within the SV40 promoter/enhancer
element and exon 2 of the c-myc gene allowed us to exclude
the possibility of amplifying contaminating plasmid DNA
sequences. Immunoblotting of protein samples extracted
from M245 LCL and M245-mycl23 using a monoclonal
antibody against c-Myc demonstrated considerably higher
levels of c-Myc protein in the myc-transfected cell line com-
pared to the control cell line (Figure 2). Both control and
transfected cell lines expressed the full range of EBV latency
associated proteins (EBNA 1-6 and LMP, data not shown).
Serum dependency
Growth in reduced serum concentrations was assessed by
culturing cells in medium containing 1% FCS for 48 h and
measuring uptake of tritiated thymidine following a 4 h
pulse. Figure 3 demonstrates the results from three replicatec-myc IN EBV-IMMORTALISED MARMOSET C CELLS 929
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Figure 3 Proliferation of M245 and M245-mycl23 in low serum
concentrations was assessed by culturing cells for 2 days in
medium containing 1% foetal calf serum and measuring incor-
poration of tritiated thymidine during a 4 h period. Results are
the mean and standard error of three separate experiments.
Table I Reciprocal antibody titres to EBV viral capsid antigen
(VCA) and early antigen (EA) complexes. Serum samples were taken
at regular time points and antibody titres determined by indirect
immunofluorescence. NT - not tested; p.i. - post inoculation; < -
less than.
(A) Marmoset 244
Days p.i. VCAlgG VCAigA VCAlgM EAlgG
-34 <8 NT <8 <8
7 <8 <8 128 <8
14 8 <8 64 <8
21 8 <8 8 <8
28 16 <8 8 <8
42 32 <8 <8 <8
168 16 NT NT <8
(B) Marmoset 245
Days p.i. VCAlgG VCAIgA VCAlgM EAlgG
-34 <8 NT <8 <8
7 <8 <8 128 <8
14 <8 <8 32 <8
21 8 <8 16 <8
28 8 <8 <8 <8
42 16 <8 <8 <8
168 32 NT NT <8
(C) Marmoset 246
Days p.i. VCAlgG VCAlgA VCAlgM EAlgG
O <8 NT NT <8
7 <8 <8 8 <8
14 8 <8 16 <8
21 16 <8 <8 <8
35 32 <8 <8 <8
experiments. As can be clearly seen the myc-transfected cells
incorporated significantly more thymidine than control cells.
Tumorgenic potential ofcell lines
The tumorigenic potential of M245 LCL and M245-mycl23
was assessed by colony formation in soft agar. Whilst the
control BL cell line Raji readily formed colonies in soft agar
neither the control or myc-transfected cell lines formed col-
onies.
Inoculation of common marmosets with M245 and
M245-myc123
The c-myc transfected cell line, M245-mycl23, was inoculated
into marmosets 245 and 246. Each animal was inoculated
with 5 x I07 cells intravenously (i.v.) and 5 x I07 cells intra-
peritoneally (i.p.) under anaesthesia. As a control an equiva-
lent number of cells from the M245 LCL were inoculated via
the same routes into marmoset 244. Marmosets from mul-
tiple births are haematologically chimeric as a result of anas-
tomoses between placentas (Hetherington et al., 1981), and
are thus tolerant to each others haemopoietic cells.
EBVserology
Antibody titres to EBV antigens, as determined by indirect
immunofluorescence, are indicated in Table I. All three mar-
mosets were EBV seronegative prior to inoculation, indicat-
ing that they had not previously been infected with EBV. All
developed anti-VCA IgM responses with 7 days of inocula-
tion and IgG class antibodies to VCA were detectable 14-21
days post inoculation. IgM antibody titres fell below detect-
able levels within 28 days, but anti-VCA IgG remained de-
tectable in all animals throughout the experiment. Neither
IgG class antibodies to EA or anti-VCA IgA were detectable
at any stage.
Haematology
Haematological data for the three animals is summarised in
Table II. No significant increase in total white cell count
(WCC) was observed in the control marmoset (244) over a
period of 24 weeks following inoculation. On morphological
grounds the haematological picture of marmoset 244 re-
mained relatively stable. The only unusual feature was the
transient appearance of atypical lymphoblastoid cells 70 days
post inoculation which at their peak represented 15% of the
total WCC. These atypical cells did not persist in the circula-
tion and had virtually disappeared by day 84. In contrast,
marmoset 245 - inoculated with M245-mycl23 - developed a
large number of atypical, lymphoblastoid cells soon after
inoculation. These comprised 49% of total lymphocytes on
day 63, and still represented 13% of the total lymphocyte
count on day 168. Figure 4 shows the appearance of these
atypical cells. Despite this abnormality the total WCC was
not dramatically raised, although a 2-fold increase was
observed soon after inoculation, and the count did not return
to pre-inoculation levels until day 84. In the other marmoset
inoculated with M245-mycl23 cells the haematological pic-
ture was similar to that seen in the control animal, with only
low numbers of atypical cells detected.
Immunocytochemistry
Cytospin preparations and thin blood films from peripheral
blood obtained 84 days post inoculation from the three
animals were stained for the presence of the EBNA complex
using ACIF. Positive staining was detected in control Raji
cells, but no EBNA positive cells were detected from any of
the three animals.
Tumorigenic potential ofthe cell lines in the host animals
No evidence for malignant disease was observed in any of the
three marmosets, all of which remained well throughout the
experiment. No lymph nodes were palpable and significant
changes in weight were not observed. The marmosets were
subjected to post mortem examination 11 months after
inoculation. No gross abnormalities were observed, however
marmoset 245 had enlarged mesenteric lymph nodes com-
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Table II Haematological data. Peripheral blood was taken at
regular intervals and total white cell counts (WCC) performed. Thin
blood films were also prepared, fixed in methanol and stained with
Giemsa. PMN - polymorphonuclear cells; Lymph. - lymphocytes;
Mono. - monocytes; atypical MN - atypical mononuclear cells
(lymphoblastoid appearance); ND - not done
(A) Marmoset 244
Days Atypical
p.i. WCC PMN Lymph Mono. MN
-34 4.3 69 31 0 0
0 ND 65 31 4 0
7 3.2 74 23 3 0
14 4.0 60 31 9 0
21 3.4 69 30 1 0
28 2.0 50 46 4 0
42 3.0 57 41 0 2
56 3.2 54 42 3 1
63 ND 70 27 3 0
70 2.0 64 18 1 15
84 2.9 65 29 2 3
111 3.1 78 15 1 2
137 ND 81 17 2 0
158 ND 72 22 6 0
179 ND 54 36 8 2
(B) Marmoset 245
Days Atypical
p.i. WCC PMN Lymph Mono. MN
-34 4.0 46 52 2 0
0 ND 52 44 4 0
7 8.4 26 61 6 7
14 6.2 38 41 15 6
21 6.6 29 56 1 14
28 5.2 39 50 1 9
42 9.2 39 52 0 10
56 6.0 41 38 1 20
63 ND 32 18 1 49
70 7.2 34 22 1 43
84 5.2 32 41 2 25
111 4.9 28 49 0 23
137 ND 54 29 5 12
158 ND 30 47 10 13
179 ND 40 43 4 13
(C) Marmoset 246
Days Atypical
p.i. WCC PMN Lymph Mono. MN
-146 5.0 69 31 0 0
0 4.9 46 43 2 9
7 6.6 73 22 1 4
14 3.1 54 41 0 5
21 3.8 55 42 1 3
35 6.0 53 39 3 5
81 ND 67 30 0 3
105 ND 52 43 3 2
126 ND 55 44 0 1
pared to marmosets 244 and 246. Histological examination of
these nodes revealed no apparent abnormalities and EBNA
was not detected by ACIPx.
Discussion
It has previously been proposed that constitutive expression
of a c-myc gene in an EBV immortalised B cell is sufficient to
induce a tumorigenic phenotype (Lombardi et al., 1987). Our
previous work has indicated that this is not necessarily the
case, and this study further supports our basic observation
that constitutive expression of c-myc in a lymphoblastoid cell
is not sufficient to induce a tumorigenic phenotype (Hotchin
et al., 1990). In agreement with previously published reports
(Lombardi et al., 1987; Hotchin et al., 1990) we found that
the LCL expressing a constitutively active c-myc gene had a
reduced serum dependency when compared to its control cell
Figure 4 Photomicrographs showing morphology of mono-
nuclear cells from the peripheral blood of: a, marmoset 244
(inoculated with control M245 cells); and b, marmoset 245
(inoculated with m245-mycl23 cells). Methanol-fixed thin blood
films were stained with Giemsa and examined under a light
microscope. am - atypical mononuclear cells (lymphoblastoid
appearance); nm - normal lymphocyte; p - polymorphonuclear
cells; e - erythrocytes. Scale bar= 20mm.
line. These enhanced growth characteristics, however, were
insufficient to result in a tumorigenic phenotype, as evidenced
by growth in semi-solid medium or tumour formation in the
host animal. As we have previously stated there are a number
of possible explanations for this anomaly (Hotchin et al.,
1990). It may be that there is a threshold ofc-Myc expression
required for a transformed phenotype and our cell lines
might express lower amounts ofc-Myc relative to those used
by Lombardi et al. This could be resolved by direct com-
parison of the cell lines. Alternatively, it may be that a
further event, such as activation of ras, may have occurred in
the lines used by Lombardi et al., resulting in a tumorigenic
phenotype. We also suggested that the resistance of our cell
lines to tumorigenic change might be a consequence of our
use of a clonal population of EBV immortalised B cells for
our transfection experiments (Hotchin et al., 1990). The cell
lines used in this study were not clonal in origin, nor were
they subjected to clonal selection following transfection, thus
we feel that the differences in tumorgenicity are unlikely to
be a consequence of using a clone of B cells intrinsically
more resistant to malignant transformation.
Haematological abnormalities were observed in one of the
two animals inoculated with the myc-transfected cell line.
Large numbers of atypical mononuclear cells were observed
in the circulation of marmoset 245. We were unable to ascer-
tain the identity of these cells using standard immunocyto-
logical techniques utilising monoclonal antibodies specific for
human T and B cells (data not shown). However, it is
,Aftlj..
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unlikely that these cells were derived from the inoculated
cells since no circulating EBNA-positive cells were detected
84 days post-inoculation when the atypical cells represented
25% of the total lymphocyte count of marmoset 245. It is
possible that the abnormal cells were a consequence of a
pre-existing haematological disorder and cytogenetic studies
have revealed a reciprocal chromosome translocation involv-
ing chromosomes 2 and 9 (J.A.B., unpublished observations).
It is not known whether this translocation was present prior
to the start ofthis experiment but it was not present in either
ofthe other marmosets, nor in either of the cell lines used for
inoculation. It seems unlikely, however, that this transloca-
tion was a consequence of inoculation of the myc-transfected
cell line.
The absence of EBNA-positive circulating B cells in any of
the animals suggests that the inoculated cells were eliminated
by the cell mediated immune system, presumably as a conse-
quence of the cell lines expressing the EBV antigens known
to be recognised by EBV-specific cytotoxic T lymphocytes
(CTL), namely EBNA-2, EBNA-3, EBNA-6 and LMP
(Thorley-Lawson & Israelsohn, 1987; Moss et al., 1988; Mur-
ray et al., 1990; Burrows et al., 1990a, 1990b). This implies
that constitutive high level expression of c-myc is insufficient
to induce a phenotype capable of evading immunosurveil-
lance either by down-regulation of viral proteins or other
molecules involved in interactions with CTL. It would be
interesting to attempt further experiments in which
marmosets inoculated with myc-transfected cells were concur-
rently either immunosuppressed with cyclosporin A or
infected with malaria. It is tempting to speculate that concur-
rent inoculation ofmyc-transfected cells and immunosuppres-
sion might result in the appearance of tumours similar to the
EBV-associated lymphomas seen in humans with profound T
cell dysfunction (Thomas et al., 1991). If, as seems likely, the
T cell dysfunction caused by malaria infection is not sus-
tained following acute malaria (Whittle et al., 1984) then one
would not expect such tumours to arise following malarial
infection and inoculation of myc-transfected cells into mar-
mosets.
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